Neuroscience Focus Areas:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for UK Healthcare Professionals only

      This promotional material is intended for UK Healthcare Professionals only.
      BOTOX® (botulinum toxin type A) Prescribing Information and adverse event reporting information can be found below.

      NDO D 2
      NDO M 2

      UK-BUO-250027. DOP: May 2025.

      Neurogenic detrusor overactivity (NDO) can be debilitating and negatively affect patients’ quality of life6

      Spinal lesions caused by trauma, such as spinal cord injury (SCI), or by a progressive neurological condition, such as multiple sclerosis (MS) can lead to NDO7,8

      The consequences of untreated NDO can result in hospitalisation with life-threatening conditions such as:6,9,10

      Urinary dysfunction is very common in patients with MS and SCI

      - Up to 80% of patients with MS report some form of urinary incontinence11

      - 81% of patients with SCI report some degree of bladder dysfunction within 1 year of injury12

      Bladder symptoms are often inadequately managed

       Patients with MS have bladder symptoms that are often not adequately managed13

       Approximately 51% of patients with moderate to severe LUTS are on anticholinergic therapy14

      • <14% of patients started on oxybutynin and tolterodine (two of the most common oral OAB medications) continued treatment
      for 1 year15
      • Median of 31 days until discontinuation15

       Poor oral therapy adherence may be linked to:13

      • UTI, retention and obstruction
      • Systemic complications
      • Increased hospitalisation rates

       Urologists/urogynaecologists should work closely with neurologists in order to optimally manage NDO

      Spectrum of treatments for NDO8,16

      X1470 NDO UK BOTOX Sales Aid - New Branding_6

      Adapted from EAU Guidelines 2020 and NICE Guidelines 20128,16

      NB: not all treatments mentioned here are licensed for NDO in the UK.

      LUTS: lower urinary tract symptoms; MS: multiple sclerosis; NDO, neurogenic detrusor overactivity; OAB: overactive bladder; SCI: spinal cord injury; UTI: urinary tract infection.

      HOW TO DIAGNOSE NDO

       

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
      4. AbbVie Data on file. Approval Dates for BOTOX® in UK. REF-112127.
      5. BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk.
      6. Tubaro A. Defining overactive bladder: epidemiology and burden of disease. Urology. 2004;64(suppl 6A);2–6
      7. Abrams P et al. Incontinence: 6th Edition 2017;50
      8. Blok B, et al. EAU Guidelines on Neuro-Urology. 2025. Available at: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Neuro-Urology-2025.pdf. Accessed June 2025.
      9. de Seze M, Ruffion A et al. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Multiple Sclerosis. 2007;13:915–928
      10. Goldmark E, Niver B and Ginsberg D A. Neurogenic bladder: from diagnosis to management. Curr Urol Rep. 2014;15:448
      11. National US MS Society. Available at: https://www.nationalmssociety.org. Accessed June 2025.
      12. Ginsberg D. The epidemiology and pathophysiology of neurogenic bladder. Am J Manag Care. 2013;19:S191-S196
      13. Manack A, Motsko S P et al. Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database. Neurourol Urodyn. 2011;30:395–401 
      14. Mahajan S T, Patel P B et al. Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS Patient Registry. J Urol. 2010;183:1432–1437
      15. Watanabe J H, Campbell J D et al. Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder. Urology. 2010;76:835–840
      16. National Institute for Health and Care Excellence (NICE). CG148: Urinary incontinence in neurological disease. Available at: https://www.nice.org.uk/guidance/cg148. Accessed June 2025.

       

      References

      1. Allergan. Data on file. INT/0423/2016
      2. Aurora S K, Winner P et al. Onabotulinum toxin A for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache. 2011;51(9):1358-1373
      3. Blumenfeld A M, Stark R J et al. Long-term study of the efficacy and safety of Onabotulinum toxin A for the prevention of chronic migraine: COMPEL study. J Headache Pain. 2018;19(1):13
      4. AbbVie Data on file. Approval Dates for BOTOX® in UK. REF-112127.
      5. BOTOX® Summary of Product Characteristics. Available at: www.medicines.org.uk.
      6. Tubaro A. Defining overactive bladder: epidemiology and burden of disease. Urology. 2004;64(suppl 6A);2–6
      7. Abrams P et al. Incontinence: 6th Edition 2017;50
      8. Blok B, et al. EAU Guidelines on Neuro-Urology. 2025. Available at: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Neuro-Urology-2025.pdf. Accessed June 2025.
      9. de Seze M, Ruffion A et al. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Multiple Sclerosis. 2007;13:915–928
      10. Goldmark E, Niver B and Ginsberg D A. Neurogenic bladder: from diagnosis to management. Curr Urol Rep. 2014;15:448
      11. National US MS Society. Available at: https://www.nationalmssociety.org. Accessed June 2025.
      12. Ginsberg D. The epidemiology and pathophysiology of neurogenic bladder. Am J Manag Care. 2013;19:S191-S196
      13. Manack A, Motsko S P et al. Epidemiology and healthcare utilization of neurogenic bladder patients in a US claims database. Neurourol Urodyn. 2011;30:395–401 
      14. Mahajan S T, Patel P B et al. Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS Patient Registry. J Urol. 2010;183:1432–1437
      15. Watanabe J H, Campbell J D et al. Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder. Urology. 2010;76:835–840
      16. National Institute for Health and Care Excellence (NICE). CG148: Urinary incontinence in neurological disease. Available at: https://www.nice.org.uk/guidance/cg148. Accessed June 2025.

      Please refer to the BOTOX® Summary of Product Characteristics for further information on adverse events, contraindications and special warnings and precautions for use. The BOTOX® Summary of Product Characteristics can be found here

      BOTOX® PRESCRIBING INFORMATION

      By clicking the link above you will leave the AbbVie Pro website and be taken to the eMC PI portal website.

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com 

       

      Date of preparation: June 2025. UK-BUO-250050.

       

       

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-250217. Date of preparation June 2025. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.